Atrophy

·MeSH: Atrophy

66 drugs in development·40 companies·2 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
estradiol	Amneal Pharmaceuticals, Inc. (AMRX)
estradiol	Mylan II B.V. (MYL)
Evrysdi	PTC THERAPEUTICS, INC. (PTCT)
Evrysdi	Royalty Pharma plc (RPRX)
imvexxy	TherapeuticsMD, Inc. (TXMD)
Spinraza	Royalty Pharma plc (RPRX)
SPINRAZA	BIOGEN INC. (BIIB)
SYFOVRE	Apellis Pharmaceuticals, Inc. (APLS)

Phase 3(15)

Drug	Company
ANX007	Annexon, Inc. (ANNX)
apitegromab	Scholar Rock Holding Corp (SRRK)
APL-2, Pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
APL-3007, pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
Nusinersen	BIOGEN INC. (BIIB)
Nusinersen	Scholar Rock Holding Corp (SRRK)
Pegcetacoplan	Apellis Pharmaceuticals, Inc. (APLS)
Risdiplam	Scholar Rock Holding Corp (SRRK)
salanersen	BIOGEN INC. (BIIB)
Salanersen (BIIB115)	BIOGEN INC. (BIIB)
sham	IVERIC bio, Inc. (ISEE)
tak-341	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
taldefgrobep alfa	Biohaven Ltd. (BHVN)
tev-56286	Teva Pharmaceutical Industries Limited (TEVA)
Vonaprument	Annexon, Inc. (ANNX)

Phase 2(18)

Drug	Company
ADX-038	ARS Pharmaceuticals, Inc. (SPRY)
Apitegromab	PTC THERAPEUTICS, INC. (PTCT)
APL-3007	Apellis Pharmaceuticals, Inc. (APLS)
argx-119 iv	ARGENX SE (ARGX)
BI 1584862	Crinetics Pharmaceuticals, Inc. (CRNX)
foralumab	Tiziana Life Sciences Ltd (TLSA)
fwy003	Novartis AG (NVS)
fwy003	NOVARTIS AG (NVSEF)
JNJ-81201887	Clearside Biomedical, Inc. (CLSDQ)
JNJ-81201887	Crinetics Pharmaceuticals, Inc. (CRNX)
lasofoxifene	IO Biotech, Inc. (IOBT)
ngm621	NGM BIOPHARMACEUTICALS INC (NGM)
Nusinersen	PTC THERAPEUTICS, INC. (PTCT)
opregen	Lineage Cell Therapeutics, Inc. (LCTX)
Risdiplam	PTC THERAPEUTICS, INC. (PTCT)
sar446597	Sanofi (SNY)
tak-341	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
Triamcinolone	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 1(5)

Drug	Company
AJ201	AVENUE THERAPEUTICS, INC. (ATXI)
avxs-101	AveXis, Inc. (AVXS)
ion464	IONIS PHARMACEUTICALS INC (IONS)
Pozelimab	REGENERON PHARMACEUTICALS, INC. (REGN)
stk-002	Stoke Therapeutics, Inc. (STOK)

Preclinical(8)

Drug	Company
4D-175	4D Molecular Therapeutics, Inc. (FDMT)
ABO-505	ABEONA THERAPEUTICS INC. (ABEO)
ALPHA-0702	Alpha Cognition Inc. (ACOG)
ALPHA-0802	Alpha Cognition Inc. (ACOG)
ic-500	IVERIC bio, Inc. (ISEE)
pas-nomacopan	Akari Therapeutics Plc (AKTX)
stl-182	SPOTLIGHT INNOVATION INC. (STLT)
szn-113	Surrozen Inc. (SRZN)

Unknown(1)

Drug	Company
ath434	Alterity Therapeutics Limited (ATHE)

Phase 1/Phase 2(4)

Drug	Company
ABBV-6628	AbbVie Inc. (ABBV)
gb221	IMMAGE BIOTHERAPEUTICS CORP. (IMMG)
SAR446597	Sanofi (SNY)
SYFOVRE	AbbVie Inc. (ABBV)

Phase 2/Phase 3(2)

Drug	Company
avacincaptad pegol	IVERIC bio, Inc. (ISEE)
ocu410	Ocugen, Inc. (OCGN)

Phase 4(5)

Drug	Company
leuprorelin	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
leuprorelin	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
onasemnogene abeparvovec	Novartis AG (NVS)
onasemnogene abeparvovec	NOVARTIS AG (NVSEF)
Triamcinolone	Clearside Biomedical, Inc. (CLSDQ)

BioSniper tracks 66 drugs in development for Atrophy across 40 companies.

There are 2 clinical trials targeting Atrophy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.